DEA issues Immediate Suspension Orders to a Tennessee pharmacy over Controlled Substances Act violations - DEA.gov
DEA has issued Immediate Suspension Orders to a Tennessee pharmacy for Controlled Substances Act violations, suspending its DEA registration and operations.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. The specific Tennessee pharmacy that received the Immediate Suspension Orders, and by extension, all pharmacies under DEA jurisdiction as a warning. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate, as the order is effective upon issuance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The pharmacy's DEA registration is immediately suspended, meaning it can no longer handle controlled substances.
Who it affects
The specific Tennessee pharmacy that received the Immediate Suspension Orders, and by extension, all pharmacies under DEA jurisdiction as a warning.
What you must do
The pharmacy must immediately cease all activities involving controlled substances and comply with the suspension order.
Deadline
Immediate, as the order is effective upon issuance.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court - kff.org
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
- Prisma Health Midlands to Pay $1 Million to Resolve Alleged Controlled Substance Act Violations - DEA.gov